What we do Gufic Biosciences Ltd is a leading Indian pharmaceutical company specializing in lyophilized injections, active pharmaceutical ingredients, and generic formulations for domestic and international markets. |
Founded in 1,984 |
Market share Among India's top 100 pharmaceutical firms, leading lyophilized injectable manufacturer and growing export footprint in regulated markets. |
Problem solved Addresses critical healthcare needs with advanced injectable solutions across antibiotics, antifungals, cardiac care, infertility, and antivirals. |
Top clients or who we serve Serves hospitals, clinics, and pharmaceutical companies globally with APIs, generics, and CMO services. B2B and B2C focus. |
Key management - |
Our journey and innovations Started as bulk drug manufacturer, expanded into formulations; pioneered lyophilized injectable production with advanced facilities in Navsari and Indore. |
Where we operate India, Africa, Asia, Europe, North America, Australia, South America with growing presence in regulated global markets. |
Top products or what we offer Lyophilized injections, generic pharmaceuticals, active pharmaceutical ingredients, herbal and nutraceutical products. |
Top brands Shapers (sanitary napkins), Onergy, Stretch nil – market leaders with strong brand equity in respective categories. |
Raw materials needed Active pharmaceutical ingredients, specialized chemicals for injectable and herbal formulations. |
Raw materials supplier Sourced from domestic and international suppliers with strong quality compliance. |
Recurring vs cyclical contribution Revenue mix includes recurring sales from generics and hospital injectables with cyclical CMO contracts. |
Our industry position Leading domestic lyophilized injection manufacturer and expanding regulated market exports, cementing strong competitive position. |
Financial highlights FY25 revenue Rs. 819.8 crore, net profit Rs. 69.6 crore; steady growth with EBITDA margin ~17%. |
Geographical revenue split Approx. 80% revenue from India and 20% from exports including Europe, Africa, Americas, Asia. |
Order book - |
Whats driving growth Scale-up of Indore facility, expanding hospital injectable portfolio, regulated market approvals, and strategic international partnerships. |
Our future plans Ramp up Indore plant, expand regulated markets, enhance R&D in biologics and immuno-oncology, and deepen domestic specialty portfolios. |
Our green promise Supports green initiatives by promoting digital communication and sustainable practices. |
Our people and values About 1,988 employees fostering a culture of innovation, ethics, and inclusivity with focus on employee development. |
Key challenges ahead Managing high fixed costs from new facility scale-up and navigating complex regulatory environments in global markets. |
Interesting facts One of India's largest lyophilized injection manufacturers; first to launch dual chamber IV bags in India. |
Risks and strategy Mitigates regulatory and operational risks through robust compliance, phased capacity ramp-up, and diversified product mix. |
